Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Recruiting

Phase 1

ASC61Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Sponsor:

Gannex Pharma Co., Ltd.

Code:

NCT05287399

Conditions

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ASC61 200 mg 1

ASC61 200 mg 2

ASC61 300 mg

ASC61 400 mg

ASC61 600 mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-16. This information was provided to ClinicalTrials.gov by Gannex Pharma Co., Ltd. on 2024-09-27.